WINT (Windtree Therapeutics) Cash Flow for Dividends: $-0.09 Mil (TTM As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Windtree Therapeutics Cash Flow for Dividends?

Windtree Therapeutics WINT +100.00% Cash Flow for Dividends is $-0.09 Mil as of Sep. 2025. The stock has 2 warning signs investors should review.

Windtree Therapeutics's cash flow for dividends for the three months ended in Sep. 2025 was $0.00 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Sep. 2025 was $-0.09 Mil.

Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.

Windtree Therapeutics's quarterly payment of dividends declined from Mar. 2025 ($-0.09 Mil) to Jun. 2025 ($0.00 Mil) but then stayed the same from Jun. 2025 ($0.00 Mil) to Sep. 2025 ($0.00 Mil).

Windtree Therapeutics's annual payment of dividends stayed the same from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($0.00 Mil) but then increased from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($-0.66 Mil).

Windtree Therapeutics Cash Flow for Dividends Related Terms

Windtree Therapeutics Cash Flow for Dividends Historical Data

* Premium members only.

The historical data trend for Windtree Therapeutics's Cash Flow for Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Windtree Therapeutics Cash Flow for Dividends Chart

Windtree Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash Flow for Dividends
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -0.66

Windtree Therapeutics Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
Cash Flow for Dividends Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -0.09 0.00 0.00

Windtree Therapeutics Cash Flow for Dividends Calculation

Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cash Flow for Dividends for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.09 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow for Dividends of $-0.09 Mil mean?
Windtree Therapeutics (WINT) has a Cash Flow for Dividends of $-0.09 Mil as of Sep. 2025. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Windtree Therapeutics and its competitors.
Is Windtree Therapeutics' Cash Flow for Dividends too high?
Windtree Therapeutics' current Cash Flow for Dividends is $-0.09 Mil.
How does Windtree Therapeutics' Cash Flow for Dividends compare to VRTX and REGN?
Windtree Therapeutics' Cash Flow for Dividends of $-0.09 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow for Dividends for a Biotechnology company?
A good Cash Flow for Dividends depends on the Biotechnology industry context. However, Cash Flow for Dividends should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow for Dividends mean?
A high Cash Flow for Dividends can signal that a stock is expensive relative to its fundamentals. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Windtree Therapeutics and its competitors. Windtree Therapeutics's current Cash Flow for Dividends is $-0.09 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Windtree Therapeutics stock overvalued right now?
Windtree Therapeutics (WINT) has a current Cash Flow for Dividends of $-0.09 Mil. The current Cash Flow for Dividends is $-0.09 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow for Dividends calculated?
Cash Flow for Dividends is calculated from a company's financial statements. For Windtree Therapeutics (WINT), the current Cash Flow for Dividends is $-0.09 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Windtree Therapeutics Business Description

Address 2600 Kelly Road, Suite 100, Warrington, PA, USA, 18976-3622
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.